Now livetag icon
2026 State of Ecommerce: Own the AI Shopper Journey.Download Reportbanner icon
ABL Bio

August 2026

ABL Bio Market Share Analysis for August 2026

Year Founded2016
Employees51 - 200
Annual Revenue$200M - $500M
ablbio.com
ABL Bio
ABL Bio (including company regionals)
  • ablbio.com
    ablbio.com
See more website traffic and engagement information

ABL Bio Revenue up to August 2026 is 200M - 500M

revenue generated by ABL Bio top domains

ABL Bio top domains revenue over 3 years

Revenue for ABL Bio top domains


Total visits to ABL Bio's top domains

Understand ABL Bio market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

Avg. visit duration in ABL Bio's top domains

Analyze ABL Bio engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

Avg. pageviews on ABL Bio's top domains

See how ABL Bio keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

Want to gain deeper traffic insights?

Filter 20.3M+ online businesses. Discover new leads when their traffic spikes, when they start or stop using technologies, or when they get positive press.



Top technologies used by ABL Bio

These are the website technologies, by industry, used by ABL Bio top domains

Advertising (4)

Google Adsense

Google Adsense

Audio Video Media (2)

YouTube

YouTube

Content Management System (1)

Squarespace

Squarespace

Conversion & Analytics (1)

Google Analytics

Google Analytics

More Technologies

6

See all

Ready to discover high quality prospects?

Identify what technologies a website uses to craft the perfect sales pitch, and shorten the sales cycle with the Similarweb Sales Intelligence Solution.


News & Signals from ABL Bio

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsABL Bio Inc. is developing Givastomig on Jun 16th '26.Givastomig is being jointly developed by NovaBridge and South Korea-based ABL Bio, with NovaBridge as lead party holding worldwide rights excluding Greater China and South Korea.
NewsABL Bio Inc. is developing various clinical and non-clinical assets based on bispecific antibody platform.ABL Bio is developing various clinical and non-clinical assets based on its bispecific antibody platform 'Grabody'.
NewsABL Bio Inc. receives financing of $55M.ABL Bio secures $55 million from Eli Lilly to expand Grabody platform and ADC pipeline.

See all ABL Bio signals

Focus your sales teams on the most promising opportunities. By prioritizing opportunities and engaging at the right time, you can optimize efforts and close more deals.